Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 26Unknown 19Recruiting 14Active not recruiting 8Withdrawn 3Terminated 3Not yet recruiting 2Enrolling by invitation 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Ovarian Neoplasms 9Triple Negative Breast Neoplasms 8Endometrial Neoplasms 8Uterine Cervical Neoplasms 5Esophageal Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Fallopian Tube Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Small Cell Lung Carcinoma 2Recurrence 2NSCLC 2Mouth Neoplasms 2Laryngeal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Ovarian Epithelial 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Thyroid Neoplasms 1Stage III and IV Ovarian Cancer 1Squamous Non-small Cell Lung Cancer 1Solid Tumor Cancer 1Sarcoma, Kaposi 1Respiratory Tract Neoplasms 1Platinum-sensitive Relapsed Ovarian Cancer 1Platinum-Resistant Primary Peritoneal Carcinoma 1Pancreatic Intraductal Neoplasms 1PDAC - Pancreatic Ductal Adenocarcinoma 1

Interventions

toripalimab 6Cisplatin 5130-nm albumin-bound paclitaxel 5Drug Therapy 4tislelizumab 3sintilimab 3camrelizumab 3Injections 3Immune Checkpoint Inhibitors 3Fluorouracil 3Carboplatin 3nedaplatin 2anlotinib 2Radiotherapy 2Paclitaxel 2Neoadjuvant Therapy 2Irinotecan 2Esophagectomy 2potassium oxonate 1pembrolizumab 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1Watchful Waiting 1Taxes 1TP protocol 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Cell Carcinoma × Paclitaxel × Clear all
NCT07621601 2026-06-02

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Hansoh BioMedical R&D Company

Phase 3 Not yet recruiting
494 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT07554456 2026-04-28

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
90 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡